Corpus Intelligence IC Memo — PAM SPECIALTY HOSPITAL OF NEW ORLEAN 2026-04-26 17:17 UTC
IC Memo — PAM SPECIALTY HOSPITAL OF NEW ORLEAN
Investment Committee Memorandum | LA | 33 beds | Grade C | EBITDA uplift $1.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

PAM SPECIALTY HOSPITAL OF NEW ORLEAN

CCN 192009 | nan, LA | 33 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

PAM SPECIALTY HOSPITAL OF NEW ORLEAN is a 33-bed under-performing / distressed in nan, LA with $17.9M in net patient revenue and a -28.3% operating margin. The hospital serves a payer mix of 43.6% Medicare, 2.3% Medicaid, and 54.1% commercial.

Thesis: Turnaround. Our ML models identify $1.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -28.3% to -20.9% (+736bps).

Net Revenue HCRIS$17.9M
Current EBITDA COMPUTED$-5.1M
Operating Margin COMPUTED-28.3%
Occupancy HCRIS58.4%
Revenue / Bed COMPUTED$544K
Net-to-Gross HCRIS28.2%
Distress Probability ML47.0%

2. Market Context & Competitive Position

212
LA Hospitals
-3.5%
State Median Margin
131
Comparable Hospitals

LA has 212 Medicare-certified hospitals with a median operating margin of -3.5%. The target's margin of -28.3% places it below the state median. Among 131 size-comparable peers (16-66 beds), the median margin is -3.5%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (16-66), prioritizing same-state peers. 131 hospitals in the comp set.

HospitalStateBedsRevenueMargin
PAM SPECIALTY HOSPITAL OF NEW (Target)LA33$17.9M-28.3%
UNIVERSITY HOSPITAL & CLINICSLA52$158.9M-33.4%
SOUTHERN REGIONAL MEDICAL CORPLA64$97.3M-50.0%
NEW ORLEANS EAST HOSPITALLA60$77.6M-29.7%
OCHSNER BAYOU LLCLA25$76.5M-0.9%
OUR LADY OF THE ANGELS HOSPITALA36$76.2M-4.9%
CENTRAL LOUISIANA SURGICAL HOSLA24$69.1M7.7%
ABBEVILLE GENERAL HOSPITALLA44$68.5M3.4%
ST. CHARLES PARISH HOSPITALLA27$64.0M-5.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$377K+210bp18mo
Cost to Collect4.5%2.5%$359K+200bp12mo
Denial Rate Reduction12.0%6.5%$355K+198bp12mo
A/R Days Reduction5200.0%3800.0%$218K+122bp9mo
Clean Claim Rate88.0%96.0%$11K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$377K
Cost to Collect
$359K
Denial Rate Reduction
$355K
A/R Days Reduction
$218K
Clean Claim Rate
$11K
Total EBITDA Uplift$1.3M
Current EBITDA$-5.1M
+ RCM Uplift+$1.3M
Pro Forma EBITDA$-3.8M
Current Margin-28.3%
Pro Forma Margin-20.9%
WC Released (1x)$688K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-7.8M$-20.3M0.00x-100.0%
Base (11x exit)10.0x11.0x$-7.8M$-24.8M0.00x-100.0%
Bull Case9.0x11.0x$-7.0M$-23.0M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-7.0M$-27.2M0.00x-100.0%
Bear Case11.0x10.0x$-8.6M$-24.3M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-8.6M$-29.5M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 131 hospitals with 16-66 beds
  • Same-state prioritization (n=132)
  • Comp margins: P25=-20.0% / P50=-3.5% / P75=4.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.